Chief global commercialization officer Mancini sells $347,402 of RVMD stock

Anthony Mancini, the Chief Global Commercialization Officer at Revolution Medicines, Inc. (RVMD) on the NASDAQ, sold 1,764 shares of the company's common stock on September 18, 2026. The sale was executed at a price of $196.94 per share, amounting to a total of $347,402. This transaction was carried out according to a pre-established 10b5-1 trading plan that Mancini had established on June 11, 2026.

After these transactions, Mancini still holds 40,352 shares of RVMD common stock. The sale occurs at a time when RVMD shares have increased by 334% over the past year, now trading at $192.86 with a market capitalization of $41.19 billion. Analysts, through InvestingPro analysis, suggest that RVMD's stock may be overvalued in relation to its Fair Value.

For those interested in a more detailed analysis, they can access the comprehensive Pro Research Report and 13 ProTips for RVMD. Other recent news highlights include the FDA approval of Revolution Medicines' drug Rasonque (daraxonrasib), which was approved based on the RASolute 302 study's promising results. This approval has led to various analyst actions, including Morgan Stanley's overweight rating, Needham and Guggenheim raising their price targets, UBS increasing its target, and H.C. Wainwright emphasizing the drug's approval for specific patient groups.